The companies will work together to develop prescription digital therapeutics for patients with schizophrenia and multiple sclerosis.
On Mar. 1, 2018, Novartis announced a collaboration with Pear Therapeutics, a prescription digital therapeutics company, to develop prescription digital therapeutics using software applications designed to treat disease and improve clinical outcomes for patients.
Under the alliance, the companies will collaborate to design and develop a new therapeutic application to address underserved mental health burden in patients with multiple sclerosis. Novartis will also help Pear to advance clinical development of Thrive, a prescription digital therapeutic for treating schizophrenia.
Pear's prescription digital therapeutics are designed to deliver clinically proven treatments, including cognitive behavioral therapy, to patients through mobile and desktop applications. Once approved, the digital therapeutics may be prescribed in partnership with drug therapies and have the potential to be developed to treat a range of diseases.
The collaboration merges Novartis’ expertise in biomedical research and clinical development with Pear's experience in digital therapeutics design and implementation. Pear first gained FDA approval of prescription digital therapeutics in September 2017 for a software application with a safety and efficacy label to treat patients. In addition, the alliance supports Novartis' strategy to enable digital technology to drive medical innovation and advance R&D efforts, as stated by Novartis.
"Psychiatric and neurodegenerative diseases place a heavy physical, mental, and economic burden on patients and their families," said Jay Bradner, MD, president of the Novartis Institutes for Biomedical Research, in a company press release. "With widespread adoption of digital devices, prescription digital therapeutics could potentially play an important role in future treatment models for a range of diseases with high unmet medical need."
Source: Novartis
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.